DCM
TEVA icon

Davis Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Davis Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$2K Hold
135
– – ﹤0.01% 249
2020
Q1 		$1K Buy
+135
New +$1.38K ﹤0.01% 256

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Davis Capital Management's TEVA Position: Q2 2020 in Review

Davis Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2020 at 135 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #249.

Davis Capital Management first reported a position in TEVA in Q1 2020 and has held it in 2 quarters since. 455 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

  • Davis Capital Management held 135 shares of Teva Pharmaceuticals worth $2K as of Q2 2020.
  • Davis Capital Management left its Teva Pharmaceuticals share count unchanged in Q2 2020.
  • Teva Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2020, its #249 holding.
  • Davis Capital Management first reported a position in Teva Pharmaceuticals in Q1 2020 and has held it in 2 quarters since.
  • 455 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on Davis Capital Management's 13F filing for Q2 2020, filed 29 Jul 2020.